Table 3.

Effects of N00236460, GKA50, S 50131 and S 51434 on hepatic triglycerides (TGs), plasma free fatty acids (FFAs) and HbA1c after a 4-day or 4-week treatment, and acute antihyperglycaemic activity 6 h after oral administration in db/db mice

	Hepatic TGs		Plasma FFAs		HbA1C levels	Acute efficacy
	4 days/4 weeks		4 days/4 weeks		4 weeks	(Δglycaemia after 6 h)
N00236460	↑	↑	ns	ns	↓	−5.30 mMcd
GKA50	↑	↑	ns	ns	nsa / ↓ b	−7.16 mMcd
S 50131	↑	↑	ns	↑	ns	−4.28 mMd
S 51434	↑	ns	ns	↑	ns	−4.64 mMd

(↑) Significant increase or (↓) decrease (P < 0.05); ns, no statistical significance.

^aP = 0.06 in the present study.

^bAfter 6 weeks of treatment in db/db mice (De Ceuninck et al., 2013).

^cData from De Ceuninck et al. (2013).

^dStatistically significant (P < 0.05).